Dyslipidemia in asthma: Treatable trait, or just a common comorbidity?
10.1097/CM9.0000000000003843
- Author:
Ke DENG
1
;
Ji WANG
1
;
Brian G OLIVER
2
;
Lisa G WOOD
3
;
Gang WANG
1
Author Information
1. Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
2. Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW 2017, Australia.
3. Priority Research Center for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, New Lambton, NSW 2308, Australia.
- Publication Type:Review
- Keywords:
Asthma;
Dyslipidemia;
Immunity;
Mechanism;
Treatable trait
- MeSH:
Humans;
Asthma/complications*;
Dyslipidemias/epidemiology*
- From:
Chinese Medical Journal
2025;138(23):3097-3114
- CountryChina
- Language:English
-
Abstract:
Asthma is a diverse disease that can be categorized into various phenotypes and endotypes, including obesity-re-lated asthma and allergic asthma. "Treatable traits (TTs)" represent a new approach to managing asthma. Asthma accompanied by dyslipidemia would be a distinct asthma phenotype that is becoming increasingly common. Therefore, dyslipidemia can potentially serve as a target for the management of asthma. Nevertheless, it remains highly under-researched compared to other observable traits. Gaining knowledge about the clinical and inflammatory characteristics, underlying mechanisms, and potential therapeutic medications for asthma with dyslipidemia is crucial for its effective management. This review aimed to provide a comprehensive overview of asthma with dyslipidemia, consolidating existing knowledge and ongoing research.
